<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">Dyslipidaemia</z:e> is an important component of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> observed in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and is characterized by moderate hypertriglyceridaemia and low levels of <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>) cholesterol concentrations </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">Dyslipidaemia</z:e> contributes to increased vascular risk and is therefore a good target for therapeutic intervention in the form of glycaemic control, lifestyle measures and hypolipidaemic drugs </plain></SENT>
<SENT sid="2" pm="."><plain>It is proposed that <z:chebi fb="23" ids="18059">lipid</z:chebi> abnormalities in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are secondary consequences of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Any approach that lowers <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> would be anticipated to have a beneficial effect on <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, but in many cases patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> fail to achieve <z:mpath ids='MPATH_458'>normal</z:mpath> <z:e sem="disease" ids="C0020473" disease_type="Disease or Syndrome" abbrv="">lipidaemia</z:e> through diet, exercise and glycaemic control </plain></SENT>
<SENT sid="4" pm="."><plain>Subgroup analyses of major clinical trials suggests that <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering therapy reduces CHD risk in patients with <z:mp ids='MP_0002055'>diabetes</z:mp>, but trials performed specifically in populations of patients with <z:mp ids='MP_0002055'>diabetes</z:mp> are ongoing </plain></SENT>
<SENT sid="5" pm="."><plain>Until then, patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who have established CHD or high individual risk already warrant aggressive <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering pharmacotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>In the author's view, when ongoing studies are complete it is likely that most patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> will be prescribed <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering drugs </plain></SENT>
</text></document>